undamentalytics Newsletter
Sign in

Agilent Technologies (A) stock

Add to watchlist

Add holding +

NYSE: A NYSE Life Sciences Tools & Services Next results ~November 25, 2026

B Fundamentals grade

Agilent Technologies supplies instruments, software, services and consumables for the whole laboratory workflow, serving life sciences, diagnostics and applied markets. Its instruments include liquid and gas chromatographs, mass spectrometers, and spectroscopy and vacuum systems. It also offers pathology and tissue-staining systems, cell analysis and genomics tools, companion diagnostic tests developed with pharmaceutical partners, and a contract development and manufacturing business (including BIOVECTRA) that produces oligonucleotide active pharmaceutical ingredients.

Customers include pharmaceutical and biopharmaceutical firms, clinical and diagnostic laboratories, academic and government institutes, and companies in chemicals, food, environmental testing and forensics. Agilent earns money from instrument sales, recurring consumables and services such as repairs, maintenance and training, software licences and subscriptions, and contract manufacturing services. It sells mainly through its own direct salesforce, supplemented by distributors, resellers, agents and electronic commerce.

Incorporated in Delaware in 1999, the company is organised into three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets — following a reorganisation announced in November 2024. It employed roughly 18,100 people worldwide as of 31 October 2025, with research and manufacturing sites in the United States and ten other countries.

Based on Agilent Technologies's 10-K filed December 22, 2025.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$85

Cash-flow model

Base case. Range ~$62–$120 across our lower- and higher-growth cases (0.2%–10.2% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 50% below it.

Price used: $171.99, November 2, 2026

Agilent Technologies valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds581 adding, 427 cuttingOf 93 active managers that changed their stake, 42 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Agilent Technologies files

Where Agilent Technologies stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $7.37bn, up 8.6% on a year earlier, slower than 9.1% a quarter earlier. That growth ranks 2 of 9 among the life sciences tools & services companies we cover. Free-cash-flow margin rose to 17.2% from 16.0% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 5 of our 7 financial-health checks. Our cash-flow model value is $78.62 a share, against a share price of $174. At that price, our model says the market is pricing in about 18.6% a year of cash-flow growth for five years, faster than the 3.1% a year revenue growth it has delivered.

Source: 10-Q filed September 1, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 25, 2026 (estimated)

Agilent Technologies's trailing-twelve-month revenue grew 8.6% year on year, with a free-cash-flow margin of 17.2%. Where it stands out: operating margin of 22.2% ranks 2 of 52 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$85 per share in the base case (~$62–$120 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 9% in the quarter to 2026-07-31, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Agilent Technologies's latest figures clears our strength thresholds.

Things to watch

  • Priced above our value. The share price of $171.99 is 50% above our value per share of $85.
  • Below peers: days sales outstanding. Days sales outstanding of 73 days ranks 38 of 48 life sciences tools & services companies we cover (median 62 days).

Latest results: FY2026 Q3

Filed September 1, 2026
Earnings per share
$1.62 against an average estimate of $1.49: beat by 9.0%
Revenue
$1.88bn, up 8.1% on a year earlier
Share reaction
+1.9% in the first session after the results on August 26, 2026, against +0.7% for the S&P 500
Guidance given
fiscal year 2026 revenue $7.49bn to $7.51bn (Fiscal year 2026); non-GAAP fiscal year 2026 operating margin expansion 130 (fiscal year 2026)
Next report
November 25, 2026; average EPS estimate $1.73

Agilent Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week-2.3%
  • 1 month+2.7%
  • This year+27.3%
  • 1 year+18.4%
  • 5 years+12.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$7.4B
Operating margin
22.2%
Net margin
19.5%
EPS (TTM, diluted)
$5.08

Growth

Revenue growth
+8.6%
Change in growth rate
−0.5 pts
Share count change
−0.9%

Cash

Free cash flow (TTM)
$1.3B
FCF margin
17.2%
Stock pay % of revenue
1.8%

Earnings

Last results
August 26, 2026
Next results (est.)
November 25, 2026

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Product
  2. Results

    Agilent sets 23 November for Q4 fiscal 2026 results

    Agilent Technologies said it will report fourth-quarter fiscal year 2026 financial results after the market closes on Monday, 23 November. The company will host a conference call at 1:30 p.m. PST to discuss the figures. A recording of the call will be available on the investor website for 90 days.

    Company releaseRead source ↗
  3. Product

    Agilent sets up energy materials research centre at University of Chicago

    Agilent Technologies said it has established a Centre of Excellence for Energy Materials Research at the University of Chicago. The facility, based at the Pritzker School of Molecular Engineering, will use Agilent mass spectrometry and atomic spectroscopy to support battery research. The centre aims to help scientists investigate next-generation energy storage materials for electric vehicles and grid systems.

    Company releaseRead source ↗
  4. Deal

    Agilent to buy Proscia for $240m in cash

    Agilent Technologies said it has agreed to acquire Proscia in an all-cash deal worth $240 million, with up to $30 million in additional milestone payments. The transaction, expected to close early in fiscal 2027, adds a digital pathology software platform to Agilent's portfolio. Proscia serves more than 4,000 laboratories and reported trailing twelve months revenue exceeding $18 million.

    Company releaseRead source ↗
  5. Announcement

    Agilent launches NovoStation for automated flow cytometry

    Agilent Technologies said it has launched the NovoStation Sample Preparation System to automate flow cytometry workflows. The company stated that validation studies showed a reduction in hands-on time by more than 90%, with one assay dropping from 89.4 minutes to 6.8 minutes. Agilent will unveil the system at the ICCS 2026 conference in Miami from Oct. 2-6, 2026.

    Company releaseRead source ↗
  6. Announcement
  7. Product
  8. Dividend
  9. Dividend
  10. Leadership
  11. Product
  12. Results
  13. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Agilent Technologies valuation models and calculator

What the price is pricing in

The share price implies about 17.7% a year of cash-flow growth for five years.That is faster than the 3.1% a year revenue growth Agilent Technologies has delivered.

  • Priced in17.7%
  • Last 12 months8.6%
  • 3 years a year1.8%
  • 5 years a year3.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($176.03, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$85
Price used
$176.03close November 3, 2026
Implied change
▼ 52%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Agilent Technologies's free cash flow after stock-based pay with after-tax interest added back ($1.3B, FY2026 Q3 TTM), growing 6.3% and 5.6% in the next two years (forecasts, guidance and its record), then back to 5.2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$62–~$120 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Agilent Technologies's free cash flow after stock-based pay ( $1.3B, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Agilent Technologies as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$85 ~$62–$120 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$160 ~$120–$210 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$97 ~$71–$140 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$80 ~$69–$95 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$100 ~$80–$160 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Agilent Technologies with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −27%
  • Revenue growth 5 points higher ▲ +35%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▲ +7%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $58$82$114$155$209$279
8.5% $43$60$83$112$151$201
10% $33$47$64$87$116$154

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$40.32$63.57$61.09$72.06$97.94$151.96$134.35$101.09$128.30$145.27$171.99
Market value$13.3bn$20.7bn$19.9bn$22.9bn$30.6bn$46.7bn$40.3bn$29.9bn$37.3bn$41.4bn$48.7bn
+ Net debt (− = net cash)−$385m−$667m−$2.2bn$1.0bn$918m$1.2bn$1.7bn$1.1bn$2.1bn$1.6bn$2.2bn
Enterprise value$12.9bn$20.1bn$17.6bn$23.9bn$31.5bn$47.9bn$42.0bn$31.1bn$39.4bn$43.0bn$50.9bn
Multiples
Price / sales 3.2x4.6x4.0x4.4x5.7x7.4x5.9x4.4x5.7x6.0x6.6x
Price / earnings 28.7x30.3x62.8x21.4x42.5x38.6x32.1x24.1x29.0x31.8x33.8x
Price / free cash flow 20.3x29.1x21.8x26.5x38.1x36.0x39.5x20.3x27.2x35.9x38.5x
EV / EBITDA 15.0x19.7x15.8x20.3x27.3x28.7x21.7x19.2x22.6x24.3x26.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

87 /100

Strong moat

How hard Agilent Technologies's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 14.7% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 53.7%, moving by 1.0 percentage points (standard deviation) across 10 years.

  • Durability 16 / 20

    Operating margin has been a median 20.3%; its worst year was 15.3%.

  • Cash conversion 19 / 20

    Free cash flow was positive in 10 of 10 years, at a median 17.0% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 8.1% over five years; stock-based pay has been a median 1.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (92 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 25, 2026, after the close. Analysts expect revenue of $2.0bn and EPS of $1.73 (range $1.71 to $1.74) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $6.20 +11% $7.5bn +8%
Next $6.73 +9% $8.0bn +6%

Next year's EPS estimate has moved +1.7% in 90 days, across 22 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.3% on 90 days ago. In the last 30 days, 2 analysts raised Agilent Technologies's forecast and 0 cut it.

Consensus EPS forecast Agilent Technologies, last 90 days
$6.00 $6.20 $6.40 $6.60 $6.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $6.06 Current fiscal year, 60 days ago: $6.20 Current fiscal year, 30 days ago: $6.20 Current fiscal year, 7 days ago: $6.20 Current fiscal year, Now: $6.20 $6.20 Next fiscal year, 90 days ago: $6.61 Next fiscal year, 60 days ago: $6.75 Next fiscal year, 30 days ago: $6.76 Next fiscal year, 7 days ago: $6.75 Next fiscal year, Now: $6.73 $6.73

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $6.06$6.61
60 days ago $6.20$6.75
30 days ago $6.20$6.76
7 days ago $6.20$6.75
Now $6.20$6.73

Earnings against estimates

Quarter toEstimateActualSurprise
Jul 2026 $1.49 $1.62 +9.0%
Apr 2026 $1.41 $1.49 +5.8%
Jan 2026 $1.37 $1.36 −0.6%
Oct 2025 $1.58 $1.59 +0.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 26, 2026
  • Fiscal year 2026 revenue Fiscal year 2026 $7.49bn to $7.51bn Raised
    “Fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion, representing a range of up 7.8% to 8.1% reported and up 5.8% to 6.0% core, (1)(5) an increase of 65 basis points at the midpoint.” source
  • Fourth-quarter 2026 revenue Fourth-quarter 2026 $1.98bn to $2bn
    “Fourth-quarter 2026 revenue is expected in the range of $1.98 billion to $2.0 billion, growth of 6.4% to 7.4% reported and up 5.2% to 6.2% core (1)(5) .” source
  • Non-GAAP fiscal year 2026 EPS fiscal year 2026 $6.18 to $6.21 Non-GAAP Raised
    “Non-GAAP fiscal year 2026 EPS (4) is now expected in the range of $6.18 to $6.21, an increase of 15 cents at the midpoint (including $0.06 net benefit from tariff refunds in the third quarter) versus our prior guide.” source
  • Non-GAAP EPS Fourth-quarter 2026 $1.71 to $1.74 Non-GAAP
    “Non-GAAP EPS (4) is expected in the range of $1.71 to $1.74 per share.” source
  • Non-GAAP fiscal year 2026 operating margin expansion fiscal year 2026 about 130 Non-GAAP Raised
    “Non-GAAP fiscal year 2026 operating margin expansion (2) at the midpoint of core revenue growth guidance is now expected to be over 130 basis points (including approximately 30 basis points in net benefit from tariff refunds in the third quarter).” source
  • Future amortization of intangibles per quarter about $27m
    “Future amortization of intangibles is expected to be approximately $27 million per quarter.” source

How earlier guidance turned out

  • Fiscal third-quarter 2026 revenue, Fiscal third-quarter 2026 guided $1.83bn to $1.85bn Above range: $1.878bn

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Agilent Technologies's revenue by +6.3% next year and +5.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+6.6%, weight 57%) , management guidance (+6.6%, weight 19%) and the company's own record (+5.2%, weight 25%) . How the weights are set.

Analyst recommendations

22 analysts, Oct 2026
Buy1568%
Hold732%
Sell00%

Monthly trend

  1. Oct 2026312722
  2. Sep 2026411722
  3. Aug 2026412622
  4. Jul 2026512421

Counts of recommendations published by analysts covering Agilent Technologies, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.0%
of tradable shares
Days to cover
2.03
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
0.2%
of shares
Employees
18,200
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +18.4%

$145.27 on October 31, 2025 to $171.99

ThenNowEffect
Revenue (last 12 months) $6.8bn $7.4bn +8.6%
Net margin 18.0% 19.5% +8.7%
P/E multiple 34.0x 33.8x −0.6%
Share count 286m 283m +0.9%

Biggest factor: net margin.

Last 3 years +61.3%

$106.61 on November 3, 2023 to $171.99

ThenNowEffect
Revenue (last 12 months) $7.0bn $7.4bn +5.4%
Net margin 16.2% 19.5% +20.6%
P/E multiple 27.9x 33.8x +21.3%
Share count 297m 283m +4.7%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
A+36%−6%−6%−3%+2%+27%
Industry peers (median)+4%−53%−3%−15%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
A83%42%42%50%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
A−17%−29%−36%−19%−35%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 43% from September 3, 2021 to April 8, 2025. Getting back needed a 76% gain, reached on September 28, 2026, 538 days after the low.

Price behaviour

52-week range
$109.61 – $181.48
From 52-week high
−5.2%
vs 50-day average
+4.7%
vs 200-day average
+26.6%
Volatility (1 year)
33%
Beta vs S&P 500
0.90

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±5.4%
After a week
7 up, 5 down
typical move ±6.6%
After a month
8 up, 4 down
typical move ±9.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 26, 2026 +1.9% +0.7% −2.2% +11.6%
May 27, 2026 +17.6% +0.5% +19.4% +18.2%
February 25, 2026 −2.8% +0.3% −3.1% −8.8%
November 24, 2025 +3.9% +2.4% −1.6% −8.5%
August 27, 2025 +5.6% +0.6% +8.6% +4.3%
May 28, 2025 +1.8% −0.2% +3.3% +7.1%
February 26, 2025 −5.3% −1.5% −5.7% −11.3%
November 25, 2024 +0.4% +0.9% +4.1% +1.5%
August 21, 2024 +0.3% −0.4% +0.9% +0.2%
May 29, 2024 −11.3% −1.4% −9.9% −12.5%
February 27, 2024 +4.2% +0.1% +9.8% +12.1%
November 20, 2023 +9.5% +0.6% +10.2% +22.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Agilent Technologies’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Includes results

A results date falls inside these options’ life. Implied volatility is meant to be higher for that, so we do not call it rich.

  • Implied is 1.58× the last 60 days’ realised volatility .
  • Puts and calls are priced at about the same implied volatility.
  • Why: an earnings date falls inside the option's life, so implied volatility is expected to be high.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

A Agilent Technologies Grade B $172.78

Own 100 shares, sell the $175 call expiring December 18, 2026 (46 days) for $8.40 a share — $840 per contract.

Previous session · Bid $8.40, ask $9.70, quoted Mon 2 Nov, 17:13 New York time with A at $172.78. Option prices move with the shares: check the live chain at your broker before trading.

  • If A ends below $175: you keep your shares and the $840 — 4.9% extra on the position, 38.6% a year at that pace.
  • If it ends above $175: your shares are sold at $175, a total return of 6.1% including the premium — at or above our value of ~$85.
$1.1k $0 −$3.3k Break-even $164.38 Price $172.78 ← Our value ~$85
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$840
Annualised
38.6%
Break-even
$164.38
Max gain
$1,062.5
Chance of selling
~51%

Results are expected around November 25, 2026, before this option expires: the share price can jump on results, and the premium partly reflects that.

Collar

Own the shares, buy the $165 put and sell the $175 call, both expiring December 18, 2026 (46 days).

  • Net credit of $1.10 a share ($110 per contract of 100 shares).
  • Worst case at expiry: -3.9%, if the shares fall below $165 (-4.5% from today).
  • Best case at expiry: +1.9%, if the shares rise above $175 (+1.3%); gains beyond that go to the call buyer.

Offered because the shares trade at or above our fair value of $85.00: a way to hold on with a floor under the price, paid for by giving up upside the model does not expect. Strikes near 25-delta; the put at its ask and the call at its bid. Protection has a cost over time: research on protective puts finds they have usually lowered returns.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Agilent Technologies in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Agilent Technologies
$6B $6.5B $7B $7.5B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $6.8B Revenue (TTM), FY24 Q1: $6.7B Revenue (TTM), FY24 Q2: $6.6B Revenue (TTM), FY24 Q3: $6.5B Revenue (TTM), FY24 Q4: $6.5B Revenue (TTM), FY25 Q1: $6.5B Revenue (TTM), FY25 Q2: $6.6B Revenue (TTM), FY25 Q3: $6.8B Revenue (TTM), FY25 Q4: $6.9B Revenue (TTM), FY26 Q1: $7.1B Revenue (TTM), FY26 Q2: $7.2B Revenue (TTM), FY26 Q3: $7.4B $7.4B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $6.8B
FY24 Q1 $6.7B
FY24 Q2 $6.6B
FY24 Q3 $6.5B
FY24 Q4 $6.5B
FY25 Q1 $6.5B
FY25 Q2 $6.6B
FY25 Q3 $6.8B
FY25 Q4 $6.9B
FY26 Q1 $7.1B
FY26 Q2 $7.2B
FY26 Q3 $7.4B
Revenue growth, TTM YoY Agilent Technologies
-10% -5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -0.2% Revenue growth, TTM YoY, FY24 Q1: -2.8% Revenue growth, TTM YoY, FY24 Q2: -6.4% Revenue growth, TTM YoY, FY24 Q3: -7.1% Revenue growth, TTM YoY, FY24 Q4: -4.7% Revenue growth, TTM YoY, FY25 Q1: -3.0% Revenue growth, TTM YoY, FY25 Q2: 0.6% Revenue growth, TTM YoY, FY25 Q3: 4.5% Revenue growth, TTM YoY, FY25 Q4: 6.7% Revenue growth, TTM YoY, FY26 Q1: 8.1% Revenue growth, TTM YoY, FY26 Q2: 9.1% Revenue growth, TTM YoY, FY26 Q3: 8.6% 8.6%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -0.2%
FY24 Q1 -2.8%
FY24 Q2 -6.4%
FY24 Q3 -7.1%
FY24 Q4 -4.7%
FY25 Q1 -3.0%
FY25 Q2 0.6%
FY25 Q3 4.5%
FY25 Q4 6.7%
FY26 Q1 8.1%
FY26 Q2 9.1%
FY26 Q3 8.6%
Operating margin (TTM) Agilent Technologies
19% 20% 21% 22% 23% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 19.8% Operating margin (TTM), FY24 Q1: 19.4% Operating margin (TTM), FY24 Q2: 19.5% Operating margin (TTM), FY24 Q3: 22.9% Operating margin (TTM), FY24 Q4: 22.9% Operating margin (TTM), FY25 Q1: 22.7% Operating margin (TTM), FY25 Q2: 21.4% Operating margin (TTM), FY25 Q3: 21.3% Operating margin (TTM), FY25 Q4: 21.3% Operating margin (TTM), FY26 Q1: 20.6% Operating margin (TTM), FY26 Q2: 21.5% Operating margin (TTM), FY26 Q3: 22.2% 22.2%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 19.8%
FY24 Q1 19.4%
FY24 Q2 19.5%
FY24 Q3 22.9%
FY24 Q4 22.9%
FY25 Q1 22.7%
FY25 Q2 21.4%
FY25 Q3 21.3%
FY25 Q4 21.3%
FY26 Q1 20.6%
FY26 Q2 21.5%
FY26 Q3 22.2%
FCF margin (TTM) Agilent Technologies
10% 15% 20% 25% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 21.6% FCF margin (TTM), FY24 Q1: 24.5% FCF margin (TTM), FY24 Q2: 23.3% FCF margin (TTM), FY24 Q3: 21.8% FCF margin (TTM), FY24 Q4: 21.1% FCF margin (TTM), FY25 Q1: 20.1% FCF margin (TTM), FY25 Q2: 17.9% FCF margin (TTM), FY25 Q3: 16.0% FCF margin (TTM), FY25 Q4: 16.6% FCF margin (TTM), FY26 Q1: 14.1% FCF margin (TTM), FY26 Q2: 15.0% FCF margin (TTM), FY26 Q3: 17.2% 17.2%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 21.6%
FY24 Q1 24.5%
FY24 Q2 23.3%
FY24 Q3 21.8%
FY24 Q4 21.1%
FY25 Q1 20.1%
FY25 Q2 17.9%
FY25 Q3 16.0%
FY25 Q4 16.6%
FY26 Q1 14.1%
FY26 Q2 15.0%
FY26 Q3 17.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Agilent Technologies took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $6.9B
  2. Cost of revenue $3.3B · 47.6%
  3. Gross profit $3.6B · 52.4%
  4. Research and development $455M · 6.5%
  5. Selling, general and admin $1.7B · 24.6%
  6. Operating income $1.5B · 21.3%
  7. Income tax $132M · 1.9%
  8. Interest and other $44M · 0.6%
  9. Net income $1.3B · 18.8%

Shares of revenue. Source: Agilent Technologies's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Oct 2009 2010 Oct 2010 2011 Oct 2011 2012 Oct 2012 2013 Oct 2013 2014 Oct 2014 2015 Oct 2015 2016 Oct 2016 2017 Oct 2017 2018 Oct 2018 2019 Oct 2019 2020 Oct 2020 2021 Oct 2021 2022 Oct 2022 2023 Oct 2023 2024 Oct 2024 2025 Oct 2025 LTM Jul 2026
Income
Revenue 4,481 5,444 6,615 6,858 3,894 4,048 4,038 4,202 4,472 4,914 5,163 5,339 6,319 6,848 6,833 6,510 6,948 7,372
Gross profit 2,292 2,930 3,529 3,604 1,907 1,976 2,041 2,197 2,409 2,680 2,805 2,837 3,407 3,722 3,465 3,535 3,643 3,968
EBITDA 209 768 1,324 1,420 758 803 775 861 1,019 1,114 1,179 1,154 1,668 1,935 1,621 1,745 1,767 1,910
Operating income 47 566 1,071 1,119 386 419 522 615 807 904 941 846 1,347 1,618 1,350 1,488 1,479 1,639
Net income −31 684 1,012 1,153 734 549 401 462 684 316 1,071 719 1,210 1,254 1,240 1,289 1,303 1,440
Diluted EPS −$0.09 $1.94 $2.85 $3.27 $2.13 $1.62 $1.20 $1.40 $2.10 $0.97 $3.37 $2.30 $3.94 $4.18 $4.19 $4.43 $4.57 $5.08
Growth (year on year)
Revenue −22.4% +21.5% +21.5% +3.7% −43.2% +4.0% −0.2% +4.1% +6.4% +9.9% +5.1% +3.4% +18.4% +8.4% −0.2% −4.7% +6.7% +8.6%
EBITDA −79.0% +267.5% +72.4% +7.3% −46.6% +5.9% −3.5% +11.1% +18.4% +9.3% +5.8% −2.1% +44.5% +16.0% −16.2% +7.6% +1.3% +10.4%
Operating income −94.1% — +89.2% +4.5% −65.5% +8.5% +24.6% +17.8% +31.2% +12.0% +4.1% −10.1% +59.2% +20.1% −16.6% +10.2% −0.6% +13.5%
Net income −104.5% — +48.0% +13.9% −36.3% −25.2% −27.0% +15.2% +48.1% −53.8% +238.9% −32.9% +68.3% +3.6% −1.1% +4.0% +1.1% +18.0%
Diluted EPS −104.8% — +46.9% +14.7% −34.9% −23.9% −25.9% +16.7% +50.0% −53.8% +247.4% −31.8% +71.3% +6.1% +0.2% +5.7% +3.2% +19.1%
Margins
Gross margin 51.1% 53.8% 53.3% 52.6% 49.0% 48.8% 50.5% 52.3% 53.9% 54.5% 54.3% 53.1% 53.9% 54.4% 50.7% 54.3% 52.4% 53.8%
EBITDA margin 4.7% 14.1% 20.0% 20.7% 19.5% 19.8% 19.2% 20.5% 22.8% 22.7% 22.8% 21.6% 26.4% 28.3% 23.7% 26.8% 25.4% 25.9%
Operating margin 1.0% 10.4% 16.2% 16.3% 9.9% 10.4% 12.9% 14.6% 18.0% 18.4% 18.2% 15.8% 21.3% 23.6% 19.8% 22.9% 21.3% 22.2%
Net margin −0.7% 12.6% 15.3% 16.8% 18.8% 13.6% 9.9% 11.0% 15.3% 6.4% 20.7% 13.5% 19.1% 18.3% 18.1% 19.8% 18.8% 19.5%
Free-cash-flow margin 6.2% 11.0% 16.2% 15.1% 24.6% 13.0% 10.3% 15.6% 15.9% 18.5% 16.8% 15.0% 20.5% 14.9% 21.6% 21.1% 16.6% 17.2%
Cash flow
Cash from operations 408 718 1,260 1,228 1,152 731 512 793 889 1,087 1,021 921 1,485 1,312 1,772 1,751 1,559 1,609
Capital spending 128 121 188 194 195 205 98 139 176 177 155 119 188 291 298 378 407 342
Free cash flow 280 597 1,072 1,034 957 526 414 654 713 910 866 802 1,297 1,021 1,474 1,373 1,152 1,267
Stock-based pay 71 66 72 74 85 96 54 58 60 70 72 83 110 125 111 129 128 132
Free cash flow after stock pay 209 531 1,000 960 872 430 360 596 653 840 794 719 1,187 896 1,363 1,244 1,024 1,135
Balance sheet
Cash 2,479 2,649 3,527 2,351 2,675 2,218 2,003 2,289 2,678 2,247 1,382 1,441 1,484 1,053 1,590 1,329 1,789 1,758
Total debt 2,905 3,691 2,185 2,362 2,699 1,663 1,655 1,904 2,011 — 2,407 2,359 2,729 2,769 2,735 3,390 3,354 3,949
Net debt (negative = net cash) 426 1,042 −1,342 11 24 −555 −348 −385 −667 −2,247 1,025 918 1,245 1,716 1,145 2,061 1,565 2,191
Diluted shares 346m 353m 355m 353m 345m 338m 335m 329m 326m 325m 318m 312m 307m 300m 296m 291m 285m 283m
Returned to shareholders
Dividends — 0 0 104 156 176 133 150 170 191 206 222 236 250 265 274 282 286
Buybacks 157 411 497 172 900 200 267 434 194 422 723 469 788 1,139 575 1,150 425 380
Total returned 157 411 497 276 1,056 376 400 584 364 613 929 691 1,024 1,389 840 1,424 707 666

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · July 31, 2026
What it owns · $14.0bn
Short-term assets $4.7bnLonger-term assets $9.3bn
What it owes, and who funded it · $14.0bn
Short-term liabilities $2.3bnLonger-term liabilities $4.3bnShareholders' equity $7.4bn
  • Short-term assets cover short-term liabilities $4.7bn of assets due within a year against $2.3bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4.7bn short-term assets against $4.3bn of longer-dated liabilities.
  • More cash than debt $1.8bn of cash against $3.9bn of debt.
  • Debt below 40% of shareholders' equity Debt is 54% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 53% to 54% over five years.
  • A year's operating cash flow covers at least 20% of debt $1.6bn of operating cash flow against $3.9bn of debt.
  • Operating profit covers interest at least five times over Operating income of $1.6bn against $106m of interest.

From Agilent Technologies's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$380M
Dividends (TTM)
$286M
Returned to shareholders
53%
of free cash flow
Buybacks, last 3 fiscal years
$2.1B
Diluted share count
−0.9%
year over year
Total shareholder yield
1.4%
dividends 0.6% + buybacks 0.8% of market value
Dividend payout ratio
20%
of net income paid out
R&D spending
6.6%
of revenue
Sales & admin spending
25.0%
of revenue
Days sales outstanding
73 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated A AVTR ICLR WAT ILMN MTD Median
Revenue, last 12 months $7.4bn $6.6bn $8.3bn $4.6bn $4.5bn $4.1bn $229m
Revenue growth, last 12 months 8.6% 0.9% 0.8% 52.5% 5.8% 6.9% 6.9%
Revenue growth, 3-year average 1.8% −1.9% 83.5% 15.8% 0.5% 1.5% 2.9%
Revenue growth, latest quarter 8.1% 4.6% — 113.3% 4.2% 4.5% 8.5%
Gross margin 53.8% 31.6% 28.6% 59.3% 67.9% 60.3% 51.9%
Operating margin 22.2% 7.3% 5.4% 7.1% 21.2% — −14.3%
Operating margin, 3-year average 22.1% 6.9% 10.5% 20.5% 4.2% — −22.4%
Net margin 19.5% 5.1% 2.8% 3.6% 19.7% 21.9% −16.1%
Cash from operations / revenue 21.8% 8.8% 12.6% 11.8% 27.1% 23.6% 1.3%
Free-cash-flow margin 17.2% 6.6% 10.4% 9.4% 23.3% 20.9% −2.2%
Free-cash-flow margin, 3-year average 18.3% 8.5% 14.4% 17.5% 19.7% 22.3% 0.6%
Stock pay / revenue 1.8% 0.7% 1.2% 1.6% 5.9% 0.6% 4.4%
Change in share count −0.9% −0.6% −4.9% 25.7% −2.1% −3.0% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 8.6% 6.9% 24 of 54
Change in growth rate Growth -0.5pp +0.4pp 34 of 54
Gross margin Profitability 53.8% 52.0% 19 of 45
Operating margin Profitability 22.2% -14.3% 2 of 52
Net margin Profitability 19.5% -12.2% 5 of 54
Free-cash-flow margin Cash generation 17.2% -1.3% 10 of 54
Stock pay as % of revenue Cash generation 1.8% 4.4% 12 of 53
Long-term debt as % of assets Balance sheet 26.1% 26.3% 16 of 35
Change in share count Balance sheet -0.9% 1.0% 15 of 46
Days sales outstanding Balance sheet 73 days 62 days 38 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to October 31, 2025
Segments
Line of business Revenue Share YoY
Agilent Cross Lab $2.9B 41.9% ▲ 5.9%
Life Sciences and Diagnostics Markets $2.7B 39.2% ▲ 10.5%
Applied Markets $1.3B 18.9% ▲ 1.3%
Products and services
Line of business Revenue YoY
Products $4.9B ▲ 5.8%
Non Instrumentation and Other $4.5B ▲ 8.8%
Instrumentation $2.4B ▲ 3.1%
Other services $2B ▲ 9.0%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue YoY
Rest of World $3.4B ▲ 11.0%
Americas $2.8B ▲ 9.1%
United States $2.3B ▲ 4.3%
Asia Pacific $2.2B ▲ 2.4%
Europe $1.9B ▲ 8.6%
China $1.2B ▲ 0.6%

These categories overlap or exclude eliminations, so shares aren't shown.

From Agilent Technologies's 10-K filed December 22, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$34.5B
Institutions reporting
1,116
Shares held vs prior quarter
▲ 3.0%
Positions opened / closed
132 / 76

Top buyers and sellers, Q2 2026: 581 institutions bought and 427 sold ; the biggest buyer was FMR LLC (+4.2M shares) and the biggest seller Cantillon Capital Management LLC (−2.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $3.4B 25.6M 9.9% ▼ 1.2%
Vanguard Capital Management LLC $2.5B 18.4M 7.1% ▲ 0.4%
Vanguard Portfolio Management LLC $1.9B 14.4M 5.6% ▲ 0.6%
State Street Corp $1.7B 12.9M 5.0% ▲ 0.7%
Massachusetts Financial Services Co $1.4B 10.0M 3.9% ▼ 20.7%
T. Rowe Price Investment Management, Inc. $1B 7.8M 3.0% ▼ 13.7%
Geode Capital Management, LLC $1B 7.6M 2.9% ▲ 1.0%
Wellington Management Group LLP $990M 7.5M 2.9% ▲ 2.7%
Deutsche Bank Ag\ $931M 7.0M 2.7% ▲ 17.1%
Bank Of New York Mellon Corp $695M 5.2M 2.0% ▲ 87.4%
Morgan Stanley $689M 5.2M 2.0% ▲ 4.8%
FMR LLC $674M 5.1M 2.0% ▲ 453.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Agilent Technologies's complete shareholder register. Values are as reported by the filers ; 5 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $3.2M 6 trades by 3 insiders · 63% under pre-set plans
Net ▼ $3.2M net selling
Insider Date Trade Shares Price Value
Dolsten Mikael Director September 4, 2026 Sell 634 $151.38 $95,972
Dolsten Mikael Director May 29, 2026 Sell 1,600 $135.42 $216,672
Dolsten Mikael Director December 1, 2025 Sell 2,600 $149.81 $389,511
Gonsalves Rodney V.P., Corporate Controller November 26, 2025 Sell 3,000 $154.99 $464,956
Mcdonnell Padraig President and CEO November 18, 2025 Sell pre-set plan 911 $143.24 $130,492
Mcdonnell Padraig President and CEO November 12, 2025 Sell pre-set plan 12,490 $150.00 $1.9M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 18 trades and filings

No trades in Agilent Technologies disclosed in the last 12 months; 18 earlier trades on record.

  • Julie Johnson(D-TX 32):Sale (full), $1,001 - $15,000, traded September 23, 2025, filed August 5, 2026
  • Julie Johnson(D-TX 32):Purchase, $1,001 - $15,000, traded September 23, 2025, filed August 5, 2026
  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded July 16, 2025, filed August 13, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 25, 2026 estimated from the company's past filing pattern, not announced

  • August 26, 2026
  • May 27, 2026
  • February 25, 2026
  • November 24, 2025
  • August 27, 2025
  • May 28, 2025

Recent SEC filings

Data status

When each part of this page on Agilent Technologies was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Agilent Technologies in brief

What does Agilent Technologies do?
Agilent Technologies is a US-listed company in the life sciences tools & services industry. Its financial year ends in October.
What is Agilent Technologies's stock ticker?
Agilent Technologies trades under the ticker A on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Agilent Technologies's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Agilent Technologies reported revenue of $7.4B, 8.6% higher than a year earlier, according to its SEC filings.
What is Agilent Technologies's free cash flow?
Agilent Technologies's free-cash-flow margin is 17.2% of revenue over the trailing twelve months, ranking 10 of the 54 life sciences tools & services companies we cover.
What is Agilent Technologies's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Agilent Technologies's free cash flow after stock-based pay gives ~$85 per share in the base case, and ~$62–$120 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Agilent Technologies's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Agilent Technologies buying back stock, and does it pay a dividend?
Agilent Technologies spent $380M on share repurchases over the trailing twelve months, and its diluted share count fell 0.9% over the year.
What is Agilent Technologies's market cap?
On November 2, 2026, Agilent Technologies's market capitalisation was about $48.7B, with a price-to-earnings ratio of 33.8 and net debt of $2.2B. Market figures come from third-party market data and may be delayed.
Does Agilent Technologies pay a dividend?
Yes: Agilent Technologies paid $286M in dividends over the trailing twelve months, a dividend yield of 0.59% and a payout ratio of 19.9%.
How much debt does Agilent Technologies have?
Agilent Technologies's debt-to-equity ratio is 53.6%, from its latest balance sheet (53.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Agilent Technologies's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Agilent Technologies are Avantor, Inc., Icon PLC, Waters Corporation, Illumina, Inc. and Mettler Toledo. The side-by-side comparison below sets their revenue, margins and growth against Agilent Technologies's.
Are insiders buying or selling Agilent Technologies stock?
Over the last 12 months, Agilent Technologies's directors and officers reported 0 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is Agilent Technologies's next earnings date?
Around November 25, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Agilent Technologies announces its own schedule.